Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.14% | 3.85% | 0.51% | 2.05% | -4.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.14% | 3.85% | 0.51% | 2.05% | -4.16% |
| Cost of Revenue | 1.18% | 11.49% | 5.80% | 8.27% | -1.76% |
| Gross Profit | 1.11% | -2.87% | -3.84% | -2.90% | -6.25% |
| SG&A Expenses | 1.72% | 6.26% | 2.36% | 4.75% | -0.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.66% | 5.90% | 0.22% | 6.32% | 0.47% |
| Operating Income | 43.88% | -13.38% | 3.03% | -20.80% | -54.16% |
| Income Before Tax | -927.10% | 202.23% | -150.03% | 114.86% | -83.02% |
| Income Tax Expenses | -938.66% | 208.34% | -142.80% | 115.50% | -81.90% |
| Earnings from Continuing Operations | -923.59% | 200.59% | -152.34% | 114.68% | -83.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -923.59% | 200.59% | -152.34% | 114.68% | -83.33% |
| EBIT | 43.88% | -13.38% | 3.03% | -20.80% | -54.16% |
| EBITDA | 21.36% | -5.63% | 6.96% | -12.20% | -30.41% |
| EPS Basic | -953.64% | 204.39% | -154.34% | 115.31% | -82.99% |
| Normalized Basic EPS | -6.89% | 9.96% | 9.30% | -21.54% | -31.56% |
| EPS Diluted | -953.83% | 204.23% | -154.41% | 115.30% | -82.97% |
| Normalized Diluted EPS | -6.85% | 9.82% | 9.44% | -21.54% | -31.54% |
| Average Basic Shares Outstanding | -3.52% | -3.65% | -3.67% | -4.12% | -2.02% |
| Average Diluted Shares Outstanding | -3.57% | -3.52% | -3.79% | -4.11% | -2.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |